Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

被引：127

作者：

Lyke, Kirsten E. ^{[1
]}

Atmar, Robert L. ^{[2
]}

Islas, Clara Dominguez ^{[3
]}

Posavad, Christine M. ^{[3
,4
]}

Szydlo, Daniel ^{[5
]}

Chourdhury, Rahul Paul ^{[5
]}

Deming, Meagan E. ^{[1
]}

Eaton, Amanda ^{[6
]}

Jackson, Lisa A. ^{[7
]}

Branche, Angela R. ^{[8
]}

Sahly, Hana M. El ^{[2
]}

Rostad, Christina A. ^{[9
]}

Martin, Judith M. ^{[10
]}

Johnston, Christine ^{[3
,4
,11
]}

Rupp, Richard E. ^{[12
]}

Mulligan, Mark J. ^{[13
]}

Brady, Rebecca C. ^{[14
]}

Frenck, Robert W., Jr. ^{[14
]}

Backer, Martin ^{[15
]}

Kottkamp, Angelica C. ^{[13
]}

Babu, Tara M. ^{[11
]}

Rajakumar, Kumaravel ^{[10
]}

Edupuganti, Srilatha ^{[16
,17
]}

Dobrzynski, David ^{[8
]}

Coler, Rhea N. ^{[18
,19
]}

Archer, Janet I. ^{[20
]}

Crandon, Sonja ^{[21
]}

Zemanek, Jillian A. ^{[5
]}

Brown, Elizabeth R. ^{[3
]}

Neuzil, Kathleen M. ^{[1
]}

Stephens, David S. ^{[16
]}

Post, Diane J. ^{[21
]}

Nayak, Seema U. ^{[21
]}

Suthar, Mehul S. ^{[22
]}

Roberts, Paul C. ^{[21
]}

Beigel, John H. ^{[21
]}

Montefiori, David C. ^{[23
]}

DMID Std Grp

机构：

[1] Univ Maryland Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA

[2] Baylor Coll Med, Dept Med & Mol Virol & Microbiol, Houston, TX 77030 USA

[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA USA

[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Lab Med & Pathol, Seattle, WA USA

[5] Univ Washington, Stat Ctr HIV AIDS Res & Prevent SCHARP, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Duke Univ Med Ctr, Dept Surg, Durham, NC USA

[7] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA

[8] Univ Rochester, Dept Med, Div Infect Dis, Rochester, NY USA

[9] Emory Univ Sch Med & Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines, Dept Pediat, Atlanta, GA USA

[10] Univ Pittsburgh Sch Med, Dept Pediat, Pittsburgh, PA USA

[11] Univ Washington, Dept Med, Seattle, WA USA

[12] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX USA

[13] NYU Langone Vaccine Ctr, NYU Grossman Sch Med, Dept Med, Div Infect Dis & Immunol, New York, NY USA

[14] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA

[15] NYU Langone Hosp, Mineola, NY USA

[16] Emory Univ Sch Med, Dept Med, Atlanta, GA USA

[17] Hope Clin Emory Vaccine Ctr, Atlanta, GA USA

[18] Univ Washington Sch Med, Seattle Childrens Res Inst, Seattle, WA USA

[19] Univ Washington Sch Med, Dept Pediat, Seattle, WA USA

[20] FHI360, Durham, NC 27701 USA

[21] Natl Inst Allergy & Infect Dis, NIH, Div Microbiol & Infect Dis, Bethesda, MD USA

[22] Emory Univ, Atlanta, GA USA

[23] Duke Univ Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 07期

基金：

美国国家卫生研究院;

关键词：

BA.2.12.1; BA.4/BA.5; booster; COVID-19; mRNA vaccine; neutralizing antibody; Omicron variant; recombinant adenovirus vaccine; SARS-CoV-2; sublineage;

D O I：

10.1016/j.xcrm.2022.100679

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to generate protective immunity. We assess the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. All prime-boost combinations substantially increase the neutralization titers to Omicron, although the boosted titers decline rapidly within 2 months from the peak response compared with boosted titers against the prototypic D614G variant. Boosted Omicron neutralization titers are substantially higher for homologous mRNA vaccine boosting, and for heterologous mRNA and Ad26.COV2.S vaccine boosting, compared with homologous Ad26.COV2.S boosting. Homologous mRNA vaccine boosting generates nearly equivalent neutralizing activity against Omicron sublineages BA.1, BA.2, and BA.3 but modestly reduced neutralizing activity against BA.2.12.1 and BA.4/BA.5 compared with BA.1. These results have implications for boosting requirements to protect against Omicron and future variants of SARS-CoV-2.

引用

页数：13

共 50 条

[31] Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan
Priyambodo, Seto
Kuo, Kuang-Che
Weng, Ken-Pen
Liu, Shih-Feng
Syu, Guan-Da
Kuo, Ho-Chang
ANNALS OF MEDICINE, 2025, 57 (01)
[32] The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China
Chu, Jinjin
Dai, Qigang
Dong, Chen
Kong, Xiaoxiao
Tian, Hua
Li, Chuchu
Peng, Jiefu
Xu, Ke
Ju, Hao
Bao, Changjun
Hu, Jianli
Zhu, Liguo
FRONTIERS IN PUBLIC HEALTH, 2024, 12
[33] Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice
van Vuren, Petrus Jansen
McAuley, Alexander J.
Kuiper, Michael J.
Singanallur, Nagendrakumar Balasubramanian
Bruce, Matthew P.
Riddell, Shane
Goldie, Sarah
Mangalaganesh, Shruthi
Chahal, Simran
Drew, Trevor W.
Blasdell, Kim R.
Tachedjian, Mary
Caly, Leon
Druce, Julian D.
Ahmed, Shahbaz
Khan, Mohammad Suhail
Malladi, Sameer Kumar
Singh, Randhir
Pandey, Suman
Varadarajan, Raghavan
Vasan, Seshadri S.
VIRUSES-BASEL, 2022, 14 (04):
[34] A booster dose of Delta x Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Lee, I-Jung
Sun, Cheng-Pu
Wu, Ping-Yi
Lan, Yu-Hua
Wang, I-Hsuan
Liu, Wen-Chun
Yuan, Joyce Pei-Yi
Chang, Yu-Wei
Tseng, Sheng-Che
Tsung, Szu-, I
Chou, Yu-Chi
Kumari, Monika
Lin, Yin-Shiou
Chen, Hui-Feng
Chen, Tsung-Yen
Lin, Chih-Chao
Chiu, Chi-Wen
Hsieh, Chung-Hsuan
Chuang, Cheng-Ying
Cheng, Chao-Min
Lin, Hsiu-Ting
Chen, Wan-Yu
Hsu, Fu-Fei
Hong, Ming-Hsiang
Liao, Chun-Che
Chang, Chih-Shin
Liang, Jian-Jong
Ma, Hsiu-Hua
Chiang, Ming-Tsai
Liao, Hsin-Ni
Ko, Hui-Ying
Chen, Liang-Yu
Ko, Yi-An
Yu, Pei-Yu
Yang, Tzu-Jing
Chiang, Po-Cheng
Hsu, Shang-Te
Lin, Yi-Ling
Lee, Chong-Chou
Wu, Han-Chung
Tao, Mi-Hua
JOURNAL OF BIOMEDICAL SCIENCE, 2022, 29 (01)
[35] Importation of SARS-CoV-2 Omicron variant in Beijing, China
Li, Fu
Liang, Zhichao
Cui, Shujuan
Lv, Bing
Feng, Zhaomin
Xu, Hui
Jia, Lei
Yang, Peng
Wang, Quanyi
Pan, Yang
Zhang, Daitao
BIOSAFETY AND HEALTH, 2022, 4 (03) : 150 - 153
[36] Importation of SARS-CoV-2 Omicron variant in Beijing, China
Li Fu
Liang Zhichao
Cui Shujuan
Lv Bing
Feng Zhaomin
Xu Hui
Jia Lei
Yang Peng
Wang Quanyi
Pan Yang
Zhang Daitao
生物安全与健康（英文）, 2022, 04 (03) : 150 - 153
[37] Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies
Kannan, Saathvik R.
Spratt, Austin N.
Sharma, Kalicharan
Chand, Hitendra S.
Byrareddy, Siddappa N.
Singh, Kamal
JOURNAL OF AUTOIMMUNITY, 2022, 126
[38] SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
Law, John Lok Man
Logan, Michael
Joyce, Michael A.
Landi, Abdolamir
Hockman, Darren
Crawford, Kevin
Johnson, Janelle
LaChance, Gerald
Saffran, Holly A.
Shields, Justin
Hobart, Eve
Brassard, Raelynn
Arutyunova, Elena
Pabbaraju, Kanti
Croxen, Matthew
Tipples, Graham
Lemieux, M. Joanne
Tyrrell, D. Lorne
Houghton, Michael
VACCINE, 2021, 39 (40) : 5769 - 5779
[39] A mini review of reinfection with the SARS-CoV-2 Omicron variant
Shen, Hongwei
Chen, Dingqiang
Li, Chenglin
Huang, Tingting
Ma, Wen
HEALTH SCIENCE REPORTS, 2024, 7 (04)
[40] Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies
Aparicio, Belen
Ruiz, Marta
Casares, Noelia
Silva, Leyre
Egea, Josune
Perez, Patricia
Albericio, Guillermo
Esteban, Mariano
Garcia-Arriaza, Juan
Lasarte, Juan J.
Sarobe, Pablo
FRONTIERS IN IMMUNOLOGY, 2023, 13

← 1 2 3 4 5 →